Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osmetech Molecular Diagnostics, a division of Osmetech plc, has signed a service agreement with TriLink BioTechnologies (TriLink) for supply of reagents to the company’s recently launched eSensor Cystic Fibrosis Carrier Detection (CFCD) System and the eSensor XT-8 System for Warfarin Sensitivity. As part of the agreement, TriLink is providing Osmetech with custom oligonucleotides, which are required reagents for the eSensor detection systems.
Subscribe to our email newsletter
“TriLink provides high quality reagents which have contributed to the excellent performance of our eSensor products in the marketplace to date,” said Osmetech Molecular Diagnostics chief operating officer, Pankaj Singhal.
“TriLink is proud to work with Osmetech in the advancement of this important science and rapidly developing commercial opportunity,” said TriLink chief executive officer, Dr. Richard Hogrefe.
Osmetech Molecular Diagnostics is focused on providing cutting-edge, cost-effective molecular diagnostic technologies and tools that enable a broader range of hospitals and laboratories to offer molecular diagnostic services for improved patient care.